Download our sample post-conference report now or receive the full version by contacting us.
The 2022 ASCO Annual Meeting has concluded and in its wake lies 93 bispecific-related abstracts that have been carefully screened and added to the Beacon database. Of these 93 abstracts, 90 presented clinical trial data, and the remaining 3 presented preclinical data.
T cell engagers were the most investigated bispecific assets. The majority of the abstracts presented by disease indication were for solid tumors accounting for 60% of the abstracts, followed by 34% for blood cancer. There are currently 6 trials presenting phase 3 trial data for solid tumors and blood cancer.
For more insight please download the sample, contact us, or request a demo.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements